Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogs in Hybrid Closed-Loop Therapy for Adults with Type 1 Diabetes

What Was Tested

This randomized controlled trial looks at Insulin Aspart and Insulin Lispro.

Objective: To evaluate postprandial glucose control when applying (1) faster-acting insulin aspart (Fiasp) compared to insulin aspart and (2) ultra-rapid insulin lispro (Lyumjev) compared to insulin lispro using the CamAPS FX hybrid closed-loop algorithm.

Why It Was Studied

Research Design and Methods: the researchers undertook a secondary analysis of postprandial glucose excursions from two double-blind, randomized, crossover hybrid closed-loop studies contrasting Fiasp to standard insulin aspart, and Lyumjev to standard insulin lispro.

Endpoints included incremental area under curve (iAUC)-2h, iAUC-4h, 4 h postprandial time in target range, time above range, and time below range.

Who Took Part

The abstract describes 51 adults taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Results: Two trials with 8 weeks of data from 51 adults with type 1 diabetes were analyzed and 7137 eligible meals were included.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the adults nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.

What Was Measured

Research Design and Methods: the researchers undertook a secondary analysis of postprandial glucose excursions from two double-blind, randomized, crossover hybrid closed-loop studies contrasting Fiasp to standard insulin aspart, and Lyumjev to standard insulin lispro.

Endpoints included incremental area under curve (iAUC)-2h, iAUC-4h, 4 h postprandial time in target range, time above range, and time below range.

PubMed files the paper under topics including Diabetes Mellitus, Type 1, Postprandial Period, Insulin Lispro, Blood Glucose, Hypoglycemic Agents, Insulin Aspart and Insulin Infusion Systems.

Author keywords: Fast-acting insulin aspart, Hybrid closed loop, Postprandial glucose excursion and Ultra-rapid lispro.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart and Insulin Lispro in 51 adults.

The publication is from 2024 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Lispro compound page, all human trials.